Scarica l'app Stockscreener
1.93
0.52%
-0.01
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.94
Aprire:
$1.925
Volume 24 ore:
11,312
Relative Volume:
0.16
Capitalizzazione di mercato:
$94.66M
Reddito:
-
Utile/perdita netta:
$-9.51M
Rapporto P/E:
-10.16
EPS:
-0.19
Flusso di cassa netto:
$-10.96M
1 W Prestazione:
-2.53%
1M Prestazione:
-9.39%
6M Prestazione:
+49.61%
1 anno Prestazione:
+37.37%
Intervallo 1D:
$1.925
$1.96
Intervallo di 1 settimana:
$1.87
$2.06
Portata 52W:
$1.12
$2.55
Medicinova Inc Stock (MNOV) Company Profile
Nome
Medicinova Inc
Settore
Industria
Telefono
858-373-1500
Indirizzo
4275 EXECUTIVE SQUARE, LA JOLLA, CA
Confronta MNOV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.93 | 94.66M | 0 | -9.51M | -10.96M | -0.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-03-10 | Iniziato | Maxim Group | Buy |
| 2019-03-25 | Ripresa | B. Riley FBR | Buy |
| 2018-03-28 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-04-18 | Iniziato | Credit Suisse | Outperform |
| 2013-01-04 | Reiterato | Ladenburg Thalmann | Buy |
| 2012-05-24 | Downgrade | MLV & Co | Buy → Hold |
| 2011-10-18 | Reiterato | MLV Capital | Buy |
| 2011-06-22 | Iniziato | Global Hunter Securities | Buy |
| 2010-05-12 | Iniziato | Wedbush | Outperform |
| 2008-11-12 | Reiterato | Ladenburg Thalmann | Buy |
| 2008-05-15 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-07-09 | Iniziato | Punk, Ziegel & Co | Buy |
Mostra tutto
Medicinova Inc Borsa (MNOV) Ultime notizie
MediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.com - MarketBeat
US Exchange Penny Stocks To Watch In January 2025 - Yahoo Finance
MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com - MarketBeat
MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com - Defense World
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV) - MarketBeat
Jane Street Group LLC Takes $30,000 Position in MediciNova, Inc. (NASDAQ:MNOV) - Defense World
MediciNova (NASDAQ:MNOV) Share Price Crosses Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
MediciNova, Inc. (NASDAQ:MNOV) Shares Acquired by Geode Capital Management LLC - Defense World
MediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.com - Defense World
MediciNova (NASDAQ:MNOV) Shares Pass Above 200-Day Moving Average – Time to Sell? - Defense World
MediciNova (NASDAQ:MNOV) Stock Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com - Defense World
MediciNova (NASDAQ:MNOV) Stock Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
StockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV) - MarketBeat
MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial… - MSN
MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial - Smartkarma
Drug Trial Shows Positive Interim Results for ALS Treatment - Streetwise Reports
MediciNova Presents Study Update and Interim Analysis of - GlobeNewswire
MediciNova Reports Strong Interim Data from ALS Drug Trial, Shows Promising Correlations - StockTitan
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at D. Boral Capital - Defense World
MediciNova stock undervalued? D. Boral sees upside in ALS & MS market opportunities - Investing.com India
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Zacks sees 400% upside for MediciNova amid incoming damages from Sanofi/Novartis dispute - Kursiv Media
MNOV: Monetary Damages Due Following Sanofi/Novartis Patent Dispute Settlement - Smartkarma
MNOV: Monetary Damages Due Following Sanofi/Novartis Patent Dispute Settlement… - MSN
MediciNova, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MediciNova reports progress in ALS and Long COVID trials - Investing.com
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders - GlobeNewswire
MediciNova Partners with NIH for ALS Trial, Reports $42.3M Cash Position | MNOV Stock News - StockTitan
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver - The Manila Times
MediciNova Receives Notice of Allowance from United States - GlobeNewswire
MediciNova Secures Key Patent for Diabetes Treatment MN-001 Through 2042 | MNOV Stock News - StockTitan
MediciNova stock hits 52-week high at $2.17 amid growth - Investing.com India
MediciNova: Q3 Earnings Snapshot - Darien Times
Medicinova Inc Azioni (MNOV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.02%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):